Investigational drugs in early clinical development for portal hypertension

References

• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 May 17;383(9930):1749–1761.
   PubMed Web of Science ®Google Scholar
• Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 January;65(1):310–335.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Bosch J. Pharmacologic management of portal hypertension. Clin Liver Dis. 2014 May;18(2):303–317.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468–475.
   PubMed Web of Science ®Google Scholar
• Manne V, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol. 2014 Oct;48(9):e76–84.
   PubMedGoogle Scholar
• Manolakopoulos S, Triantos C, Theodoropoulos J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol. 2009 Sep;51(3):468–474.
   PubMed Web of Science ®Google Scholar
• Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017 Nov;153(5):1273–1283.e1.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016 Oct;65(4):692–699.
   PubMedGoogle Scholar
• de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959–974.
   PubMed Web of Science ®Google Scholar
• Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020 May;69(5):953–962.
   PubMed Web of Science ®Google Scholar
• Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012 Nov;143(5):1253–1260.e4.
   PubMed Web of Science ®Google Scholar
• Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995 May;21(5):1238–1247.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol. 2011 Sep;35(8–9):526–533.
   PubMedGoogle Scholar
• Li W, Zhang J, Huang G, et al. [Effects of heparin on the growth, extracellular matrix and matrix metalloproteinase gene expression in rat hepatic stellate cells]. Zhonghua Gan Zang Bing Za Zhi. 2000 8;Aug(4):200–202.
   Google Scholar
• Anstee QM, Goldin RD, Wright M, et al. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost. 2008 Aug;6(8):1336–1343.
   PubMedGoogle Scholar
• Abdel-Salam OM, Baiuomy AR, Ameen A, et al. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res. 2005 Jan;51(1):59–67.
   PubMedGoogle Scholar
• Li W, Zhang J, Huang Q, et al. Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl(4) or porcine serum injection. Hepatol Res. 2006 Oct;36(2):115–123.
   PubMedGoogle Scholar
• Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286–294.
   PubMedGoogle Scholar
• Assy N, Hussein O, Khalil A, et al. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci. 2007 May;52(5):1187–1193.
   PubMedGoogle Scholar
• Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014 Nov;351(2):288–297.
   PubMedGoogle Scholar
• Lee KC, Hsu WF, Hsieh YC, et al. Dabigatran reduces liver fibrosis in thioacetamide-injured rats. Dig Dis Sci. 2019 Jan;64(1):102–112.
   PubMed Web of Science ®Google Scholar
• Fortea JI, Zipprich A, Fernandez-Mena C, et al. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver Int. 2018 Jan;38(1):102–112.
   PubMedGoogle Scholar
• Cerini F, Vilaseca M, Lafoz E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016 Apr;64(4):834–842.
   PubMedGoogle Scholar
• Vilaseca M, García-Calderó H, Lafoz E, et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology. 2017 June;65(6):2031–2044.
   PubMedGoogle Scholar
• Weinberg EM, Palecki J, Reddy KR. Direct-Acting Oral Anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis. 2019 May;39(2):195–208.
   PubMedGoogle Scholar
• Hum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017 Apr;98(4):393–397.
   PubMed Web of Science ®Google Scholar
• Goriacko P, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018 May;100(5):488–493.
   PubMed Web of Science ®Google Scholar
• Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016 June;61(6):1721–1727.
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017 May;37(5):694–699.
   PubMed Web of Science ®Google Scholar
• Davis KA, Joseph J, and Nisly SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis. 2020 Aug; 50 (2): 457–461. .
   PubMedGoogle Scholar
• Turco L, de Raucourt E, Valla DC, et al. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019 Sep;1(3):227–239.
   PubMedGoogle Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Apixaban 2012 02 April 2021 . Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
   Google Scholar
• European Medicines Agency. Apixaban 2021 02 April 2021 . Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf
   Google Scholar
• Iqbal U, Dennis BB, Li AA, et al. Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. Hepatol Int. 2019 Jan;13(1):84–90.
   PubMed Web of Science ®Google Scholar
• Moore K. Endothelin and vascular function in liver disease. Gut. 2004 Feb;53(2):159–161.
   PubMedGoogle Scholar
• Møller S, Gülberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol. 1995 Aug;23(2):135–144.
   PubMedGoogle Scholar
• Hsu SJ, Lin TY, Wang SS, et al. Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats. Eur J Clin Invest. 2016 Jun;46(6):572–580.
   PubMedGoogle Scholar
• Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology. 1998 Sep;28(3):655–659.
   PubMedGoogle Scholar
• Lebrec D, Bosch J, Jalan R, et al. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. Eur J Clin Pharmacol. 2012 May;68(5):533–541.
   PubMed Web of Science ®Google Scholar
• Tripathi D, Therapondos G, Ferguson JW, et al. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut. 2006 Sep;55(9):1290–1295.
   PubMed Web of Science ®Google Scholar
• Treiber A, Äänismaa P, de Kanter R, et al. Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther. 2014 Jul;350(1):130–143.
   PubMedGoogle Scholar
• Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019 7;Jul(7):594–604.
   Google Scholar
• Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, et al. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology. 2013 Oct;58(4):1424–1435.
   PubMed Web of Science ®Google Scholar
• Di Pascoli M, Zampieri F, Verardo A, et al. Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. Hepatology. 2016 Sep;64(3):923–930.
   PubMedGoogle Scholar
• Trebicka J, Leifeld L, Hennenberg M, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology. 2008 Apr;47(4):1264–1276.
   PubMedGoogle Scholar
• Steib CJ, Bilzer M, op den Winkel M, et al. Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology. 2010 Jun;51(6):2086–2096.
   PubMedGoogle Scholar
• Bataller R, Ginès P, Nicolás JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000 Jun;118(6):1149–1156.
   PubMed Web of Science ®Google Scholar
• García-Pagán JC, Salmerón JM, Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 1994 May;19(5):1095–1099.
   PubMedGoogle Scholar
• Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009 Jun 2;150(11):776–783.
   PubMed Web of Science ®Google Scholar
• Tandon P, Abraldes JG, Berzigotti A, et al. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010 Aug;53(2):273–282.
   PubMed Web of Science ®Google Scholar
• Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004 Mar;126(3):749–755.
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J, Russo L, García-Calderó H, et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut. 2011 Apr;60(4):517–524.
   PubMed Web of Science ®Google Scholar
• Marrone G, Russo L, Rosado E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013 Jan;58(1):98–103.
   PubMedGoogle Scholar
• Marrone G, Maeso-Díaz R, García-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015 Sep;64(9):1434–1443.
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005 Dec;4(12):977–987.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009 May;136(5):1651–1658.
   PubMed Web of Science ®Google Scholar
• Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis. 2015 Nov;47(11):957–963.
   PubMedGoogle Scholar
• Bishnu S, Ahammed SM, Sarkar A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol. 2018 Jan;30(1):54–59.
   PubMedGoogle Scholar
• Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016 May;150(5):1160–1170.e3.
   PubMed Web of Science ®Google Scholar
• La Mura V, Pasarín M, Meireles CZ, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013 Mar;57(3):1172–1181.
   PubMed Web of Science ®Google Scholar
• Meireles CZ, Pasarin M, Lozano JJ, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation. Shock. 2017 Mar;47(3):370–377.
   PubMedGoogle Scholar
• Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology. 2018 Nov;155(5):1564–1577.
   PubMed Web of Science ®Google Scholar
• Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1521–1530.e8.
   PubMed Web of Science ®Google Scholar
• Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31–41.
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology. 2008 Apr;47(4):1248–1256.
   PubMedGoogle Scholar
• Laleman W, Omasta A, Van de Casteele M, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005 Dec;42(6):1382–1390.
   PubMedGoogle Scholar
• Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs. 2016 Jun;21(2):167–181.
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Mehta G, Balasubramaniyan V, et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol. 2015 Feb;62(2):325–331.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014 Jun;59(6):2286–2298.
   PubMed Web of Science ®Google Scholar
• Mookerjee R, Rosselli M, Pieri G, et al. Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2a study. J Hepatol. 2014;60(1):S7–S8.
   Google Scholar
• Úbeda M, Lario M, Muñoz L, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol. 2016 May;64(5):1049–1057.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6:33453.
   PubMed Web of Science ®Google Scholar
• Li J, Kuruba R, Wilson A, et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One. 2010 Nov;5(11):e13955.
   PubMed Web of Science ®Google Scholar
• Zhou J, Cui S, He Q, et al. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat Commun. 2020 Jan;11(1):240.
   PubMed Web of Science ®Google Scholar
• Xu W, Lu C, Zhang F, et al. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. FEBS J. 2017 Jan;284(1):114–133.
   PubMedGoogle Scholar
• Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017 Apr;66(4):724–733.
   PubMed Web of Science ®Google Scholar
• Matei V, Rodríguez-Vilarrupla A, Deulofeu R, et al. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. J Hepatol. 2008 Aug;49(2):192–197.
   PubMedGoogle Scholar
• Reverter E, Mesonero F, Seijo S, et al. Effects of sapropterin on portal and systemic hemodynamics in patients with cirrhosis and portal hypertension: a bicentric double-blind placebo-controlled study. Am J Gastroenterol. 2015 Jul;110(7):985–992.
   PubMed Web of Science ®Google Scholar
• Hong WK, Shim KY, Baik SK, et al. Relationship between tetrahydrobiopterin and portal hypertension in patients with chronic liver disease. J Korean Med Sci. 2014 Mar;29(3):392–399.
   PubMed Web of Science ®Google Scholar
• Mónica FZ, Bian K, Murad F. The endothelium-dependent nitric oxide-cGMP pathway. Adv Pharmacol. 2016;77:1–27.
   PubMedGoogle Scholar
• Loureiro-Silva MR, Iwakiri Y, Abraldes JG, et al. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol. 2006 May;44(5):886–893.
   PubMed Web of Science ®Google Scholar
• Lee KC, Yang YY, Huang YT, et al. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clin Sci (Lond). 2010 Apr;119(1):45–55.
   PubMed Web of Science ®Google Scholar
• Schaffner D, Lazaro A, Deibert P, et al. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol. 2018 Oct;24(38):4356–4368.
   PubMedGoogle Scholar
• Tandon P, Inayat I, Tal M, et al. Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol. 2010 Jun;8(6):546–549.
   PubMed Web of Science ®Google Scholar
• Clemmesen JO, Giraldi A, Ott P, et al. Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. World J Gastroenterol. 2008 Oct;14(40):6208–6212.
   PubMed Web of Science ®Google Scholar
• Paternostro RHB, Schwarzer R, Reiberger T, et al. Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo controlled trial. J Hepatol. 2018;68:717.
   Google Scholar
• Kreisel W, Deibert P, Kupcinskas L, et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015 Feb;47(2):144–150.
   PubMedGoogle Scholar
• Uschner FE, Glückert K, Paternostro R, et al. Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver Int. 2020 Sep;40(9):2228–2241.
   PubMedGoogle Scholar
• Buys ES, Zimmer DP, Chickering J, et al. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide. 2018;78:72–80.
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006 Sep;5(9):755–768.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Brusilovskaya K, Supper P, et al. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep. 2018 June;8(1):9372.
   PubMedGoogle Scholar
• Hall KC, Bernier SG, Jacobson S, et al. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc Natl Acad Sci U S A. 2019 May;116(22):11057–11062.
   PubMedGoogle Scholar
• Brusilovskaya K, Königshofer P, Lampach D, et al. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J. 2020 Dec;8(10):1174–1185.
   PubMedGoogle Scholar
• Oldenburger A, Birk G, Schlepütz M, et al. Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices. Pharmacol Res Perspect. 2021 May;9(3):e00768.
   PubMedGoogle Scholar
• Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, et al. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol. 2018;11:1756284818811294.
   Web of Science ®Google Scholar
• Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013 Jan;61(2):196–206.
   PubMed Web of Science ®Google Scholar
• Bennett RG, Heimann DG, Singh S, et al. Relaxin decreases the severity of established hepatic fibrosis in mice. Liver Int. 2014 Mar;34(3):416–426.
   PubMedGoogle Scholar
• Fallowfield JA, Hayden AL, Snowdon VK, et al. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology. 2014 Apr;59(4):1492–1504.
   PubMed Web of Science ®Google Scholar
• Lachlan NJMN, Masson N, Ireland H, et al. Serelaxin reduced portal pressure gradient and portal vein pressure in patients with cirrhosis and portal hypertension [abstract]. Hepatology. 2015;62:585a.
   Google Scholar
• Gifford FJ, Dunne PDJ, Weir G, et al. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials. 2020 Mar;21(1):260.
   PubMedGoogle Scholar
• Snowdon VK, Lachlan NJ, Hoy AM, et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial. PLoS Med. 2017 Feb;14(2):e1002248.
   PubMedGoogle Scholar
• Hernández-Guerra M, García-Pagán JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology. 2006 Mar;43(3):485–491.
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Berzigotti A, Seijo S, et al. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr. 2012 Sep;96(3):584–590.
   PubMed Web of Science ®Google Scholar
• Di Pascoli M, Diví M, Rodríguez-Vilarrupla A, et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2013 May;58(5):904–910.
   PubMedGoogle Scholar
• Laviña B, Gracia-Sancho J, Rodríguez-Vilarrupla A, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut. 2009 Jan;58(1):118–125.
   PubMedGoogle Scholar
• García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2011 Apr;54(4):660–665.
   PubMedGoogle Scholar
• Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, et al. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol. 2013 Feb;58(2):240–246.
   PubMedGoogle Scholar
• Vilaseca M, García-Calderó H, Lafoz E, et al. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver Int. 2017 July;37(7):1002–1012.
   PubMed Web of Science ®Google Scholar
• Turkseven SBM, Brocca A, Angeli P, et al. In cirrhotic rats, mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis by modulating oxidative stress and mitophagy. J Hepatol. 2018;68:S466.
   Google Scholar
• Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992 Jan;72(1):101–163.
   PubMed Web of Science ®Google Scholar
• Warskulat U, Borsch E, Reinehr R, et al. Chronic liver disease is triggered by taurine transporter knockout in the mouse. Faseb J. 2006 Mar;20(3):574–576.
   PubMedGoogle Scholar
• Younis NS, Ghanim AMH, Elmorsy MA, et al. Taurine ameliorates thioacetamide induced liver fibrosis in rats via modulation of toll like receptor 4/nuclear factor kappa B signaling pathway. Sci Rep. 2021 Jun 10;11(1):12296.
   PubMedGoogle Scholar
• Devi SL, Viswanathan P, Anuradha CV. Regression of liver fibrosis by taurine in rats fed alcohol: effects on collagen accumulation, selected cytokines and stellate cell activation. Eur J Pharmacol. 2010 Nov 25;647(1–3):161–170.
   PubMedGoogle Scholar
• Liang J, Deng X, Lin ZX, et al. Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis. World J Gastroenterol. 2009 Sep 28;15(36):4529–4537.
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Kivaranovic D, Mandorfer M, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018 Jan;47(1):86–94.
   PubMedGoogle Scholar
• Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, et al. Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis. Gastroenterology. 2007 Sep;133(3):959–966.
   PubMedGoogle Scholar
• Rahman MM, Muse AY, Khan DMIO, et al. Apocynin prevented inflammation and oxidative stress in carbon tetra chloride induced hepatic dysfunction in rats. Biomed Pharmacother. 2017 Aug;92:421–428.
   PubMed Web of Science ®Google Scholar
• Bettaieb A, Jiang JX, Sasaki Y, et al. Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, Fibrosis, and insulin sensitivity during development of steatohepatitis in mice. Gastroenterology. 2015 Aug;149(2):468–80.e10.
   PubMed Web of Science ®Google Scholar
• Boyer-Diaz Z, Domingo JC, De Gregorio E, et al. A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease. Nutrients. 2019 Oct;11(10):2358.
   Google Scholar
• Bosch J, Abraldes JG, Fernández M, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010 Sep;53(3):558–567.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005 Jul;43(1):98–103.
   PubMed Web of Science ®Google Scholar
• Coriat R, Gouya H, Mir O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One. 2011 Feb 14;6(2):e16978.
   PubMed Web of Science ®Google Scholar
• Pinter M, Sieghart W, Reiberger T, et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma–a pilot study. Aliment Pharmacol Ther. 2012 Jan;35(1):83–91.
   PubMed Web of Science ®Google Scholar
• D’Amico M, Mejías M, García-Pras E, et al. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2012 May 15;302(10):G1191–8.
   PubMed Web of Science ®Google Scholar
• Lin HC, Huang YT, Yang YY, et al. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. J Gastroenterol Hepatol. 2014 May;29(5):1073–1082.
   PubMedGoogle Scholar
• Tugues S, Fernandez-Varo G, Muñoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007 Dec;46(6):1919–1926.
   PubMed Web of Science ®Google Scholar
• Majumder S, Piguet AC, Dufour JF, et al. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol. 2013 Apr 5;705(1–3):86–95.
   PubMedGoogle Scholar
• Uschner FE, Schueller F, Nikolova I, et al. The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget. 2018 Nov 16;9(90):36220–36237.
   PubMedGoogle Scholar
• Garcia-Tsao G, Fallon MB, Reddy KR, et al. Placebo-controlled, randomized, pilot study of the effect of sorafenib on portal pressure in patients with cirrhosis, portal hypertension and ablated hepatocellular carcinoma (HCC). Hepatology. 2015;62(6):580A–581A .
   Google Scholar
• Delgado MG, Gracia-Sancho J, Marrone G, et al. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2013 Oct 1;305(7):G496–502.
   PubMedGoogle Scholar
• Tripathi DM, Erice E, Lafoz E, et al. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G301–9.
   PubMed Web of Science ®Google Scholar
• Rittig N, Aagaard NK, Sundelin E, et al. Metformin stimulates intestinal glycolysis and lactate release: a single-dose study of metformin in patients with intrahepatic portosystemic stent. Clin Pharmacol Ther. 2021 Nov;110(5):1329–1336.
   PubMedGoogle Scholar
• de Mesquita FC, Guixé-Muntet S, Fernández-Iglesias A, et al. Liraglutide improves liver microvascular dysfunction in cirrhosis: evidence from translational studies. Sci Rep. 2017 Jun 12;7(1):3255.
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113–1124.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Herring R, and Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022 Apr;16: 1–12. .
   Google Scholar
• Gracia-Sancho J, Manicardi N, Ortega-Ribera M, et al. Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism. Hepatol Commun. 2019 Jul;3(7):987–1000.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Koyama Y, Wree A, et al. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. J Mol Med (Berl). 2018 Jun;96(6):575–583.
   PubMedGoogle Scholar
• Mehta G, Rousell S, Burgess G, et al. A placebo-controlled, multicenter, double-blind, phase 2 randomized trial of the pan-caspase inhibitor emricasan in patients with acutely decompensated cirrhosis. J Clin Exp Hepatol. 2018 Sep;8(3):224–234.
   PubMed Web of Science ®Google Scholar
• Garcia‐Tsao G, Fuchs M, Shiffman M, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019 Feb;69(2):717–728.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020 May;72(5):885–895.
   PubMed Web of Science ®Google Scholar
• Frenette C, Kayali Z, Mena E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2021 Feb;74(2):274–282.
   PubMed Web of Science ®Google Scholar
• Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018 Feb;67(2):549–559.
   PubMed Web of Science ®Google Scholar
• Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979 Feb;23(2):403–411.
   PubMed Web of Science ®Google Scholar
• Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003 Jan;37(1):208–217.
   PubMed Web of Science ®Google Scholar
• Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014 Jan;60(1):197–209.
   PubMed Web of Science ®Google Scholar
• Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993 May;17(5):828–832.
   PubMed Web of Science ®Google Scholar
• Pérez-Paramo M, Muñoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000 Jan;31(1):43–48.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911–921.
   PubMed Web of Science ®Google Scholar
• Mendoza YP, Rodrigues SG, Bosch J, et al. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: a systematic review and meta-analysis. Dig Liver Dis. 2020 Sep;52(9):958–965.
   PubMedGoogle Scholar
• Hennenberg M, Trebicka J, Buecher D, et al. Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase? Liver Int. 2009 Jul;29(6):933–941.
   PubMedGoogle Scholar
• Zhu Q, Zou L, Jagavelu K, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012 Apr;56(4):893–899.
   PubMed Web of Science ®Google Scholar
• Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012 Jul;10(7):815–818.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009 May;29(9):992–999.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013 Mar;28(3):450–455.
   PubMed Web of Science ®Google Scholar
• Lim YL, Kim MY, Jang YO, et al. Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: an open randomized controlled pilot study. Gut Liver. 2017 Sep;11(5):702–710.
   PubMedGoogle Scholar
• Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 2013 Sep;33(8):1148–1157.
   PubMed Web of Science ®Google Scholar
• Kimer N, Pedersen JS, Busk TM, et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial. Hepatology. 2017 Feb;65(2):592–603.
   PubMed Web of Science ®Google Scholar
• Kemp W, Colman J, Thompson K, et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. Liver Int. 2009 Mar;29(3):427–433.
   PubMed Web of Science ®Google Scholar
• Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010 Dec;52(6):2044–2052.
   PubMed Web of Science ®Google Scholar
• Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013;8(10):e75361.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020 Apr;158(5):1334–1345.e5.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, et al. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2012 May;56(5):1033–1039.
   PubMed Web of Science ®Google Scholar
• Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006 Jun;110(3):371–385.
   PubMed Web of Science ®Google Scholar
• Aljada A, O’Connor L, Fu YY, et al. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis. 2008;11(4):361–367.
   PubMedGoogle Scholar
• Tsai HC, Li TH, Huang CC, et al. Beneficial effects of the peroxisome proliferator-activated receptor α/γ agonist aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension. Am J Pathol. 2018 Jul;188(7):1608–1624.
   PubMedGoogle Scholar
• Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021 May;74(5):1188–1199.
   PubMed Web of Science ®Google Scholar
• Francque SM, Bedossa P, Ratziu V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021 Oct 21;385(17):1547–1558.
   PubMed Web of Science ®Google Scholar
• Klein S, Frohn F, Magdaleno F, et al. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. Sci Rep. 2019 Feb 19;9(1):2256.
   PubMedGoogle Scholar
• Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018 Oct;155(4):1140–1153.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010 Mar 4;362(9):823–832.
   PubMed Web of Science ®Google Scholar
• Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol. 2015 Apr;62(1 Suppl):S121–30.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Albillos A, Genescà J, et al. βblockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019 Apr 20;393(10181):1597–1608.
   PubMed Web of Science ®Google Scholar